Furthermore, another study employing CRISPR/Cas9 technology on A20 demonstrated that genetic variation in the A20 deubiquitinase (DUB) domain increased the risk of systemic lupus erythematosus (SLE) and rheumatoid arthritis (Odqvist et al., 2019). This evidence concerns the gene ZUP1 and systemic lupus erythematosus.